NASDAQ:GH Guardant Health Q3 2026 Earnings Date & Estimates $162.09 -0.70 (-0.43%) Closing price 04:00 PM EasternExtended Trading$159.65 -2.44 (-1.51%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Guardant Health is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Guardant Health in Q3 2026Guardant Health is expected to post earnings of -$0.7526 per share on revenue of $350.67 million. In the same quarter a year earlier Guardant Health reported -$0.39 per share. Guardant Health last reported on July 30, 2026, posting -$0.42 per share and beating the -$0.7618 consensus estimate. Guardant Health has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.7526Expected Revenue$350.67 millionPrior-Year EPS-$0.39Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.42 (Beat by +$0.3418)Last Quarter Revenue$334.98 millionEPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ4 2025 Earnings ReportQ3 2025 Earnings Report Guardant Health Q3 2026 Earnings FAQ When does Guardant Health report Q3 2026 earnings? Guardant Health (NASDAQ:GH) has confirmed it will report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. What time is Guardant Health's Q3 2026 earnings call? Guardant Health's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Guardant Health? Analysts expect Guardant Health to post earnings of -$0.7526 per share for Q3 2026. How much revenue is Guardant Health expected to report? The consensus revenue estimate for Guardant Health is $350.67 million for Q3 2026. Guardant Health Earnings HeadlinesGrail (GRAL) vs Guardant Health (GH): Which is a Better Stock to Buy?October 9, 2026 | insidermonkey.comGuardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast CancerOctober 8, 2026 | uk.finance.yahoo.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.October 13 at 1:00 AM | Banyan Hill Publishing (Ad)Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026October 8, 2026 | businesswire.comGuardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in MelanomaOctober 5, 2026 | businesswire.comComparing Guardant Health (NASDAQ:GH) and The Pennant Group (NASDAQ:PNTG)October 4, 2026 | americanbankingnews.comSee More Guardant Health Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Guardant Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Guardant Health and other key companies, straight to your email. Email Address About Guardant HealthGuardant Health (NASDAQ:GH) (NASDAQ: GH) is a precision oncology company that develops blood- and tissue-based diagnostic tests designed to help detect cancer, guide treatment decisions and monitor patients throughout the course of their disease. Its testing platforms analyze circulating tumor DNA and other genomic information to provide insights into a tumor’s molecular characteristics. The company’s products include Guardant360 tests for comprehensive genomic profiling in advanced cancer, Guardant360 CDx, which is approved as a companion diagnostic for certain targeted therapies, and Guardant360 Response for assessing how a tumor may be responding to treatment. Guardant also offers Guardant Reveal, a blood-based test intended to help evaluate minimal residual disease and recurrence risk, as well as Shield, a blood test for colorectal cancer screening. Guardant Health provides testing services to physicians, hospitals, health systems, biopharmaceutical companies and research organizations. Its services support patient care, clinical research and drug development, with operations and commercial activities serving customers in the United States and international markets. The company was founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, who have held senior leadership roles at Guardant Health. The company is headquartered in Palo Alto, California.View Guardant Health ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
